A clinical study on lamivudine treatment for decompensated cirrhosis due to hepatitis B

Journal of Xi'an Jiaotong University (Medical Sciences)

Volumn 27, Issue 6, 2006, Pages 575-577

  Cai, Zhifang ^a   Shang, Fengmei ^b   Zhao, Wenxue ^a   Lü, Fangling ^a   Zhang, Zhaoxia ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Zhenghe Hospital   (China)

Author keywords

Chronic hepatitis B; Lamivudine; Liver cirrhosis

Indexed keywords

ALBUMIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ALBUMIN BLOOD LEVEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; SCORING SYSTEM; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33846365701     PISSN: 16718259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Chinese source
2. Chinese source
3. Chinese source
4. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy [J]. Gastroenterology, 2003, 124(1):105-117.
5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease [J]. N Engl J Med, 2004, 351(15):1521-1531.
6. Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis [J]. Liver Transpl, 2003, 9(1):49-56.